Track topics on Twitter Track topics that are important to you
Hutchison China MediTech (Chi-Med) announced the start of a US Phase I bridging trial of its lead drug, fruquintinib, in patients with solid tumor cancers. Fruquintinib is a VEGFR inhibitor with an anti-angiogenesis mechanism. In
Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY)
Share this with colleagues:
Original Article: Chi-Med Starts First US Trial of Fruquintinib, an Anti-Angiogenesis DrugNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...